Our findings and those of the others [21,35] provide the impetus for undertaking studies to examine in detail the spatio-temporal TrkB responses, including TrkB’s binding properties and TrkB receptor phosphorylation dynamics, in glaucoma and after treatment with a range of doses of AAV-BDNF, to establish optimal conditions for potential use in clinical trials. This evidence concerns the gene NTRK2 and glaucoma.